Abstract 6051: An Evolving Approach of Therapeutic Angiogenesis with Sustained Release of Platelet-Rich Plasma in Diabetic Mouse Hind Limb Ischemia
Diabetes (DM) is one of the negative predictors of therapeutic angiogenesis. Thus, single angiogenic cytokine therapy may be insufficient, particularly in solution form. Platelet rich plasma (PRP) has been reported to contain various cytokines and facilitates tissue regeneration. Sustained release of platelet-rich plasma may facilitate neovascularization effectively in the diabetic mouse hind limb ischemia. Growth factors concentrations were measured in PRP or in platelet-poor plasma (PPP) by ELISA. In vivo study, we used gelatin hydrogel microsphere for sustained release carrier of growth factors from PRP. Unilateral hind limb ischemia was induced by ligating the right femoral artery in streptozotocin induced DM mice. After surgery, mice were randomly assigned to following 4 experimental groups (n=10, each): control (no treatment), PRP solution (100μl) and sustained release of PPP (100μl) or sustained release of PRP (100μl); applied by single intramuscular injection and observed for 4 weeks. Tissue blood perfusion was evaluated by laser Doppler perfusion image index (ratio of right to left blood perfusion; LDPII). Capillary density and mature vessel density were calculated by staining with anti-mouse von Willebrand factor and anti- α-smooth muscle actin antibody respectively. The concentration (pg/ml) of SDF-1α (10,790 ± 196 vs. 810 ± 39), PDGF (45,352 ± 2698 vs. 958 ± 251), VEGF (53 ± 6 vs. 30 ± 2), bFGF (29 ± 5 vs. 9 ± 5), IGF-1 (20,628 ± 1,180 vs. 1,214 ± 36, mean ± S.D.) were significantly higher in group PRP than those in group PPP respectively (P < 0.05). LDPII, capillary density and mature vessel density were significantly higher in group PRP than those in other groups (table⇓). Sustained release of PRP containing multiple potent growth factors facilitated neovascularization effectively even in diabetic mouse hind limb ischemia. This can be promising therapeutic option in the future.